Successful reduction of high-sustained anti-idursulfase antibody titers by immune modulation therapy in a patient with severe mucopolysaccharidosis type II.

Mol Genet Metab Rep · 2015 · PMC5471157 · PMID 28649520

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Bortezomib was felt to be safe and the authors suggested addition of bortezomib in patients with high antibody titers (≥ 1:51,200) at or beyond 6 months on enzyme replacement therapy and/or when an increasing trend or persistence of antibody titers is associated with clinical decline.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.